SCHEMBL5568259

SCHEMBL5568259

Fc1ccc(Nc2ncnc3cc(F)ccc23)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 12/20 0.65
ABCG2 Q9UNQ0 3/20 0.57
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
CLK4 Q9HAZ1 2/20 0.54
USP2 O75604 1/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
TSHR P16473 1/20 0.54
CYP2C19 P33261 1/20 0.54
HIF1A Q16665 1/20 0.54
CD38 P28907 1/20 0.53
DAPK3 O43293 1/20 0.51
MAP4K4 O95819 1/20 0.51
ABL1 P00519 1/20 0.51
ERBB2 P04626 1/20 0.51
PIM1 P11309 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569052 0.90 EGFR (0.70) EGFRABCG2CLK4DAPK3MAP4K4
Hydrochloric Acid SCHEMBL11087812 0.89 EGFR (0.68) EGFRABCG2CLK4DAPK3MAP4K4
SCHEMBL28086820 0.89 EGFR (0.73) EGFRMEN1KMT2ACLK4USP2
SCHEMBL27878333 0.87 USP2 (0.65) EGFRABCG2MEN1KMT2ACLK4
SCHEMBL7473882 0.85 EGFR (0.68) EGFRMEN1KMT2ACLK4USP2
Hydrochloric Acid SCHEMBL8810268 0.84 KDR (0.70) EGFRABCG2KMT2ALMNAERBB2
SCHEMBL5569041 0.83 EGFR (0.75) EGFRABCG2KMT2ACLK4DAPK3
SCHEMBL5569501 0.82 EGFR (0.60) EGFRABCG2TSHR
SCHEMBL28086863 0.82 EGFR (0.77) EGFRABCG2MEN1KMT2AALDH1A1
SCHEMBL22137768 0.82 TTBK1 (0.61) EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT EGFR 1445/4885ABCG2 311/4885MEN1 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.